Armata Pharmaceuticals Inc. (ARMP) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Armata Pharmaceuticals Inc. (ARMP:NYSE), powered by AI.

Current Price
$7.58
P/E Ratio
-1.6
Market Cap
275M
Sector
Healthcare
What is the Armata Pharmaceuticals Inc. stock price forecast?

Armata Pharmaceuticals Inc. is currently trading at $7.58. View real-time AI analysis on Alpha Lenz.

What is Armata Pharmaceuticals Inc. insider trading activity?

View the latest insider trading data for Armata Pharmaceuticals Inc. on Alpha Lenz.

What is Armata Pharmaceuticals Inc.'s P/E ratio?

Armata Pharmaceuticals Inc.'s P/E ratio is -1.6.

Armata Pharmaceuticals Inc.

NYSE · ARMP
$7.58+0.11(+1.47%)Pre-marketNYSE regular session 09:30–16:00 ET
Ask about Armata Pharmaceuticals Inc.'s future dividend policy...
Alpha Chat Insight

Armata Pharmaceuticals Inc. trades at a P/E of -1.6 (undervalued) with strong ROE of 130.4%.

Ask for details

Company Overview

Armata Pharmaceuticals Inc. is a biotechnology company dedicated to the development of innovative therapies to treat antibiotic-resistant infections. Operating in the healthcare sector, the company focuses on bacteriophage-based solutions, aiming to address the growing global issue of antimicrobial resistance. Armata Pharmaceuticals specializes in researching and developing treatments derived from natural phages, viruses that specifically target and eliminate bacteria, offering an alternative to traditional antibiotics. The company’s efforts are crucial in fields impacted by resistant bacterial strains, including healthcare-associated infections and chronic illnesses linked to bacterial biofilms. With its headquarters in the United States, Armata engages in collaborations with various research institutions and industry partners, emphasizing a scientific approach alongside cutting-edge technology. Armata Pharmaceuticals holds a significant position in the biopharmaceutical market, contributing to the advancement of precision medicine and public health innovations. Its dedication to addressing unmet medical needs positions it as a key player in the development of next-generation antimicrobial therapies. By exploring bacteriophage technology, Armata aims to provide targeted, effective alternatives that could revolutionize how infections are managed globally.

CEODr. Deborah L. Birx M.D.
SectorHealthcare
IndustryBiotechnology
Employees60

Company Statistics

FY 2025

Profile

$274.69MMarket Cap
$0.00Revenue
0.00Shares Out
60Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

-1.58P/E
-1.26P/B
N/AEV/Sales
-3.69EV/EBITDA
-10.44P/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-212.83%ROA
130.37%ROE
-192.52%ROIC

Financial Health

$8.69MCash & Cash Equivalents
$286.79MNet Debt
-135.17%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Armata Pharmaceuticals Inc. (ticker: ARMP) is a company listed on NYSE in the Healthcare sector (Biotechnology). It has approximately 60 employees. Market cap is $275M.

The current price is $7.58 with a P/E ratio of -1.58x and P/B of -1.26x.

ROE is 130.37%.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Armata Pharmaceuticals Inc. (ARMP) Stock Forecast 2026 $7.58 — Price, Financials & Analyst Targets | Alpha Lenz